NVO Stock Price Today (April 2026) — Novo Nordisk A/S Analysis & Key Metrics 2026-04-02
Novo Nordisk A/S (NVO) is trading at $37.21, up 2.00% today (as of April 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $47.12 (26.6% upside).
- Volatility remains elevated (22.37% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (-7.60% YoY) alongside significant competitive pressures.
NVO Stock Analysis: Key Metrics & Valuation (April 2026)
Concise, actionable data for investors
Novo Nordisk A/S - Historical Price & Volume
Market Cap
Enterprise Value: $268.34B
P/E Ratio
Forward P/E: 10.81
Revenue Growth
Year over Year
Analyst Target
+26.6% upside potential
Key Investor Questions About NVO
What investors need to know before buying
Based on current market data, NVO presents a neutral technical setup with challenging fundamentals.
- Technicals say: Neutral (RSI 52.27)
- Fundamentals say: Challenging (declining revenue trends)
NVO's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for NVO investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $130.96B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, NVO stock traded between $35.12 and $81.44—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 22.37% annualized volatility and β=0.27, the stock exhibits low sensitivity to market moves—making NVO suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Jim Cramer Shares Why Novo Nordisk (NVO) Might Feel The Heat From Eli Lilly
We just covered Jim Cramer Discussed The Iran Ceasefire & Commented On These 19 Stocks. Novo Nordisk A/S (NYSE:NVO) is one of the stocks discussed by Jim Cramer. Novo Nordisk A/S (NYSE:NVO)’s shares are down by 40% over the past year and by 29.6% year-to-date. BMO Capital kept a Market Perform rating and a $45 […]
Update: Market Chatter: Eli Lilly, Novo Nordisk Face Pressure in India as Semaglutide Generics Gain Ground
(Updates with Novo Nordisk's comments in the fifth and sixth paragraphs.) Cheap generic versions
Alleged Ceasefire Violations in Middle East, Shipping Halt in Strait of Hormuz Dampen US Equity Futures Pre-Bell
US equity futures were lower pre-bell Thursday after Iran accused the US of violating the two-week c
Eli Lilly Weight-Loss Pill Becomes Available in U.S.
Eli Lilly’s Foundayo weight-loss pill is now available in the U.S. following the Food and Drug Administration’s approval earlier this month, the company said.
Market Chatter: Eli Lilly, Novo Nordisk Face Pressure in India as Semaglutide Generics Gain Ground
Cheap generic versions of semaglutide in India are beginning to erode the dominance of Eli Lilly's (
New weight-loss pill wins FDA approval as demand surges
Eli Lilly, the pharmaceutical giant, secured an important victory in the intensifying war against diabetes and obesity. Earlier this month, the drugmaker confirmed that the U.S. Food and Drug Administration (FDA) had approved Foundayo (orforglipron), a once-daily oral GLP-1pill for chronic weight ...
Novo Nordisk (NVO) Increases Yet Falls Behind Market: What Investors Need to Know
In the most recent trading session, Novo Nordisk (NVO) closed at $37.61, indicating a +1.9% shift from the previous trading day.
Novo-Backed Respiratory Drugmaker Avalyn Pharma Files for US IPO
(Bloomberg) -- Avalyn Pharma Inc., a biopharma company developing inhaled treatments for respiratory diseases, filed for a US initial public offering.The Boston-based company’s pipeline is focused on treating pulmonary fibrosis, a disease with a median survival rate of three to five years, according to its filing Wednesday with the US Securities and Exchange Commission. Avalyn counts Novo Holdings A/S, an investing vehicle of the controlling shareholder of weight loss drug giant Novo Nordisk A/S
Which of These Healthcare Stocks Is More Likely to Be a Millionaire Maker?
One of these players is well-positioned for market leadership.
Novo Nordisk Obesity And Diabetes Moves Tested Against Weak Share Performance
Novo Nordisk has introduced a higher dose 7.2 mg version of Wegovy at a lower price than a key rival GLP-1, aiming to sharpen its position in obesity care. The company has renewed its partnership with Hims & Hers Health to distribute obesity medications through direct to consumer channels, expanding access and reach. Following recent US FDA approval, Novo Nordisk is launching once weekly basal insulin Awiqli as a new option in diabetes treatment. For investors watching CPSE:NOVO B, these...
Frequently Asked Questions
Common investor questions about Novo Nordisk A/S
Novo Nordisk A/S (NVO) is currently trading at $37.21. The RSI (14-day) is at 52.3, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $47.12 implies 26.6% upside from current levels. Volatility is moderate at 22.4% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Novo Nordisk A/S (NVO): The trailing P/E ratio is 10.39, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 10.81. The PEG ratio is 4.89, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 5.47. Price-to-Sales is 0.53. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 12 analysts covering NVO, the consensus price target is $47.12. This represents a 26.6% upside from the current price of $37.21. The range spans from a low target of $39.85 to a high target of $63.60, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Novo Nordisk A/S (NVO) pays a dividend with a current yield of approximately 4.88%. The annualized dividend rate is $11.70 per share. The payout ratio is 50.4%, which is moderate and suggests adequate earnings coverage for the dividend. The most recent ex-dividend date was 2026-03-30.
Key risks for Novo Nordisk A/S (NVO) investors include: 1. Declining revenue (-7.6% YoY), indicating potential business headwinds. 2. Elevated short interest (77.0% of float) suggests significant bearish sentiment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Novo Nordisk A/S's (NVO) current debt and financial health profile: Total debt stands at $130.96B. The debt-to-equity ratio is 67.49, which is moderate and generally manageable for most companies. The current ratio is 0.80, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.54. The company holds $26.96B in cash and equivalents. Free cash flow is positive at $376.88M, providing a cushion for debt servicing and shareholder returns.